Skip to main content

Table 3 Characteristics of ankylosing spondylitis patients with cardiac conduction abnormalities according to conservative criteria; PQ-interval ≥ 220 ms and/or QRS complex ≥ 120 ms (n = 21)

From: Cardiac conduction system abnormalities in ankylosing spondylitis: a cross-sectional study

Age Sex Symptom duration IVCD AV block BAS DAI BASFI BAS MI HLA B27 alleles Cardio-active Rx CVD
     PM       
30 m 8 LAFB   5.76 3.2 3 1 0  
38 m 18   AV I 2.99 1.34 1.6 1 0  
43 m 14 LBBB   1.95 1.07 1.4 1 0  
50 m 27   AV I 5.03 3.45 2.8 1 0  
52 m 13   AV I 3.9 2.43 2 1 0 HT
57 m 33 RBBB AV I 3.4 2.3 3.4 1 0 Valve disease
LAFB
59 m 36 LAFB   1 0.9 5.6 1 0  
61 m 34   AV I 1 1 1.8 1 BB* HT
62 m 38 LAFB   4.65 3.88 3.6 1 (BB) Valve disease,
CAD
63 m 36 LAFB   1.38 3.69 7.2 1 0 HT
63 m 49   AV I 4.11 4.26 6 1 0  
64 m 45 LAFB   0.89 2.36 6.8 1 0 Valve disease
64 m 44 LAFB   2.34 2.53 7 1 (BB) AF; HT
68 m 39 LAFB   3.44 4.99 4.2 0 0 Valve disease
68 m 42 RBBB   5 4.56 5.6 1 0 Valve disease
HT
71 m 55 LAFB   7.1 8.7 3.4 1 (BB) HT
74 m 25 LBBB   NA NA 6 1 (BB) Valve disease,
heart failure
75 m 52   PM 3.84 6.65 7.2 1 (BB) Valve disease
HT
77 m 23 LAFB   6.78 7.9 6.8 1 (BB) Valve disease
HT
46 f 39   AV I 2.73 1.62 2.8 1 0  
62 f 46 LAFB   3.57 3.09 3.2 2 0  
  1. Noted in the right hand column are substances that might affect atrio- and/or intra-ventricular conduction; when within brackets no clinical effect is assumed in the patient.
  2. Abbreviations: AI aortic valve insufficiency, AV atrio-ventricular, AV I 1st degree AV block, BASDAI, BASFI, and BASMI1, see Table 2, BB beta-blocker, CAD coronary artery disease, CVD cardio-vascular disease, HT hypertension, IVCD intra-ventricular conduction disturbances, LAFB left anterior fascicular block, LBBB left bundle branch block, NA not available//missing data, PM pacemaker, RBBB right bundle branch block.
  3. * beta-blocker therapy might impair atrio-ventricular but not intra-ventricular conduction.